AUS
NZ
UK
CA
USA
IND
Highlights
- ASX 200 Gains: The benchmark S&P/ASX 200 Index (ASX:XJO) rises 0.4% to 8,232.7 points in afternoon trade, aiming to close the week on a high.
- Cettire shares climb 3.5% to AU$1.62 as investors seize a perceived buying opportunity despite no fresh news.
- Imugene shares increase 2.5% after dosing the first Australian patient in a Phase 1b trial for its CAR T-cell therapy.
The S&P/ASX 200 Index (ASX:XJO) is looking to wrap up the week on a positive note, rising 0.4% to 8,232.7 points in afternoon trade. Amid this upward movement, several ASX-listed shares have significantly outperformed the broader market.
Here’s a closer look at the top performers:
Cettire Ltd (ASX:CTT)
The online luxury retailer saw its share price jump 3.5% to AU$1.62 despite no new announcements. Investors appear to be snapping up shares of Cettire, which have plummeted over 40% year-to-date and 67% from their 52-week high. The sharp decline in valuation has seemingly created an attractive buying opportunity for value-focused investors.
Gold Road Resources Ltd (ASX:GOR)
Gold Road Resources shares are up nearly 3% to AU$2.12, buoyed by a strong performance in gold futures overnight. Safe-haven demand pushed the price of gold to a two-week high of US$2,668.8 per ounce, according to CNBC. This positive momentum has lifted the entire gold sector, with the S&P/ASX All Ordinaries Gold Index up 2.5% in afternoon trade.
Imugene Ltd (ASX:IMU)
Shares of biotech company Imugene rose 2.5% to 4 cents after the company announced a significant milestone in its phase 1b clinical trial for its allogeneic CAR T-cell therapy, azer-cel. The therapy, targeting relapsed or refractory diffuse large B-cell lymphoma (DLBCL), saw its first Australian patient dosed at Sydney's Royal Prince Alfred Hospital. The update underscores progress in treating one of the most aggressive forms of non-Hodgkin’s lymphoma.
